Literature DB >> 26428207

Subclinical Atherosclerosis Is Not Accelerated in Patients with Ankylosing Spondylitis with Low Disease Activity: New Data and Metaanalysis of Published Studies.

Aikaterini Arida1, Athanasios D Protogerou1, George Konstantonis1, Maria Konsta1, Evi M Delicha1, George D Kitas1, Petros P Sfikakis2.   

Abstract

OBJECTIVE: Chronic inflammatory rheumatic diseases are associated with accelerated atherosclerosis, but data in ankylosing spondylitis (AS) are limited and the relative contribution of inflammation versus classical cardiovascular (CV) risk factors remains a matter of controversy. We addressed this in an original study and a metaanalysis of previous studies.
METHODS: Atheromatic plaques in carotid and femoral arteries, carotid hypertrophy [intima-media thickness (IMT), cross-sectional area], and carotid stiffness by ultrasound, as well as aortic stiffness by pulse wave velocity, were examined in consecutive nondiabetic, CV disease (CVD)-free patients with AS. Healthy individuals carefully matched 1:1 with patients for age, sex, smoking habits, hyperlipidemia, and hypertension served as controls. A metaanalysis of original studies that examined subclinical atherosclerosis in patients with AS versus controls with comparable CVD risk factors was also performed.
RESULTS: Carotid and femoral atheromatic plaques were slightly less prevalent compared with controls in a contemporary cohort consisting of 67 patients with AS (82% men), aged 47.5 ± 12.5 years (mean ± SD), with a median disease duration of 12 years and a Bath AS Disease Activity Index (BASDAI) of 1.8 (interquartile range 0.4-3.6), of whom 66% were receiving anti-tumor necrosis factor (TNF) treatment. Carotid hypertrophy and stiffness, as well as aortic stiffness, were similar between patients and their matched controls. Metaanalysis of all published studies revealed a significantly increased carotid IMT, but not plaque burden, in AS versus controls. Notably, however, increased IMT was not evident in studies involving patients with low disease activity (mean BASDAI < 4) or in those studies that included > 50% of patients treated with anti-TNF.
CONCLUSION: Low AS disease activity is not associated with accelerated atherosclerosis.

Entities:  

Keywords:  ANKYLOSING SPONDYLITIS; ATHEROMATOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE

Mesh:

Substances:

Year:  2015        PMID: 26428207     DOI: 10.3899/jrheum.150316

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

1.  Atherogenic index of plasma: a useful marker for subclinical atherosclerosis in ankylosing spondylitis : AIP associate with cIMT in AS.

Authors:  Erkan Cure; Abdullah Icli; Ali Ugur Uslu; Davut Sakiz; Medine Cumhur Cure; Rabia Aydogan Baykara; Fatma Yavuz; Sevket Arslan; Adem Kucuk
Journal:  Clin Rheumatol       Date:  2018-02-12       Impact factor: 2.980

Review 2.  Cardiovascular Morbidity in Ankylosing Spondylitis: A Focus on Inflammatory Cardiac Disease.

Authors:  Pradnya Brijmohan Bhattad; Mugdha Kulkarni; Parasbhai D Patel; Mazen Roumia
Journal:  Cureus       Date:  2022-06-03

3.  Endothelial dysfunction and increased carotid intima-media thickness in patients with spondyloarthritis without traditional cardiovascular risk factors.

Authors:  Aicha Ben Tekaya; Seif Boukriba; Ahmed Fendri; Leila Rouached; Olfa Saidane; Selma Bouden; Rawdha Tekaya; Kamel Ben Salem; Ines Mahmoud; Mizouni Habiba; Leila Abdelmoula
Journal:  RMD Open       Date:  2022-07

4.  Assessment of aortic stiffness in patients with ankylosing spondylitis using cardiovascular magnetic resonance.

Authors:  P Stefan Biesbroek; Sjoerd C Heslinga; Peter M van de Ven; Mike J L Peters; Raquel P Amier; Thelma C Konings; Christopher D Maroules; Colby Ayers; Parag H Joshi; Irene E van der Horst-Bruinsma; Vokko P van Halm; Albert C van Rossum; Michael T Nurmohamed; Robin Nijveldt
Journal:  Clin Rheumatol       Date:  2018-05-12       Impact factor: 2.980

5.  [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Authors:  U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

Review 6.  Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases.

Authors:  Aikaterini Arida; Athanasios D Protogerou; George D Kitas; Petros P Sfikakis
Journal:  Int J Mol Sci       Date:  2018-06-27       Impact factor: 5.923

7.  Differences in carotid atherosclerosis between patients with ankylosing spondylitis treated with tumor necrosis factor-α antagonists and healthy matched controls.

Authors:  Enrico Maria Zardi; Maria Elena Pipita; Chiara Giorgi; Domenico Lichinchi; Domenico Maria Zardi; Antonella Afeltra
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

8.  Prevalence of Subclinical Carotid Atherosclerosis and Vitamin D Deficiency in Egyptian Ankylosing Spondylitis Patients.

Authors:  Dina Salem Fotoh; Dena Mamdouh Serag; Ismail Tawfeek Badr; Dalia Salah Saif
Journal:  Arch Rheumatol       Date:  2020-02-07       Impact factor: 1.472

9.  Microvascular dysfunction in ankylosing spondylitis is associated with disease activity and is improved by anti-TNF treatment.

Authors:  Bogdan Batko; Pawel Maga; Karol Urbanski; Natalia Ryszawa-Mrozek; Agata Schramm-Luc; Mateusz Koziej; Tomasz Mikolajczyk; Eilidh McGinnigle; Marta Czesnikiewicz-Guzik; Piotr Ceranowicz; Tomasz J Guzik
Journal:  Sci Rep       Date:  2018-09-04       Impact factor: 4.379

10.  Assessment of subclinical atherosclerotic cardiovascular disease in patients with ankylosing spondylitis.

Authors:  Erdinç Hatipsoylu; İlker Şengül; Taciser Kaya; Altınay Göksel Karatepe; Seniz Akçay; Leyla Isayeva; Giray Bozkaya; Erhan Tatar
Journal:  Anatol J Cardiol       Date:  2019-09       Impact factor: 1.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.